相关实验视频
Updated: Jun 28, 2025

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.4K
在患有2型糖尿病的患者中,用类似葡萄糖-1受体激活剂改善功能
1Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, Chiba 272-8516, Japan.
Journal of medical cases
|April 22, 2024
概括
-葡萄糖共载体2抑制剂 (SGLT2is) 可能会在一些患有高血压硬化症的糖尿病病患者中恶化功能. 在这些情况下,类似葡萄糖-1受体激动剂 (GLP-1RAs) 可能会改善功能.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病病 (DKD) 包含除了糖尿病病之外的各种病理.
- -葡萄糖共载体2抑制剂 (SGLT2is) 用于慢性病 (CKD) 进展风险.
- 管球球体反 (TGF) 规范化是SGLT2i益的一个拟议机制.
研究的目的:
- 为了呈现一个高血压硬化的DKD病例,SGLT2i治疗导致功能恶化.
- 探索类似葡萄糖-1受体激动剂 (GLP-1RAs) 在此类情况下改善功能方面的潜在作用.
主要方法:
- 一个患有DKD和高血压神经硬化症的2型糖尿病患者的病例报告.
- 在SGLT2i和GLP-1RA治疗后对功能变化的分析.
主要成果:
- SGLT2i治疗导致了患者的功能恶化.
- 随后的GLP-1RA治疗导致功能得到改善.
- 通过通过TGF正常化减少 afferent动脉动脉血流,SGLT2is可能会加剧高血压性神经硬化中的球性缺血症.
- 在不影响TGF的情况下,GLP-1RAs可以通过增强血管内皮功能来改善功能.
结论:
- SGLT2is可能不适合所有DKD患者,特别是患有高血压硬化的患者.
- GLP-1RAs代表了改善高血压硬症的DKD患者功能的一种潜在治疗选择.
- 由于SGLT2is和GLP-1RAs的不同机制,需要对患者进行仔细的选择,以获得最佳的CKD管理.
相关概念视频
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Dipeptidyl Peptidase 4 Inhibitors
182
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
182
Oral Hypoglycemic Agents: Biguanides and Glitazones
195
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
195
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Hypoglycemia and Glucagon
257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
Hormones Regulating Blood Glucose
3.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.3K

